TWO-YEAR CLINICAL RESPONSE TO BRODALUMAB, AN ANTI-IL-17 RECEPTOR ANTIBODY, IN PATIENTS WITH PSORIATIC ARTHRITIS

被引：2
|
作者：
Mease, P. [1 ,2 ]
Genovese, M. C. [3 ]
Greenwald, M. W. [4 ]
Ritchlin, C. T. [5 ]
Beaulieu, A. [6 ]
Deodhar, A. [7 ]
Newmark, R. [8 ]
Feng, J. [8 ]
Erondu, N. [8 ]
Nirula, A. [8 ]
机构：
[1] Swedish Med Ctr, Seattle, WA USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Stanford Univ, Palo Alto, CA 94304 USA
[4] Desert Med Adv, Palm Desert, OH USA
[5] Univ Rochester, Med Ctr, Rochester, OH USA
[6] Univ Laval, Laval, PQ, Canada
[7] Oregon Hlth & Sci Univ, Portland, OR USA
[8] Amgen Inc, Thousand Oaks, CA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2015年 / 74卷
关键词：
D O I：
10.1136/annrheumdis-2015-eular.3489
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0175
引用
收藏
页码：136 / 137
页数：2
相关论文
共 50 条
  • [31] Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinic
    Luchetti, Michele Maria
    Benfaremo, Devis
    Campanati, Anna
    Molinelli, Elisa
    Ciferri, Monia
    Cataldi, Serena
    Capeci, William
    Di Carlo, Marco
    Offidani, Anna Maria
    Salaffi, Fausto
    Gabrielli, Armando
    CLINICAL RHEUMATOLOGY, 2018, 37 (10) : 2741 - 2749
  • [32] Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinic
    Michele Maria Luchetti
    Devis Benfaremo
    Anna Campanati
    Elisa Molinelli
    Monia Ciferri
    Serena Cataldi
    William Capeci
    Marco Di Carlo
    Anna Maria Offidani
    Fausto Salaffi
    Armando Gabrielli
    Clinical Rheumatology, 2018, 37 : 2741 - 2749
  • [33] IMPAIRED REGULATORY T CELL FUNCTIONS IN PATIENTS WITH PSORIASIS ARTHRITIS ELIGIBLE TO SWITCH TO ANTI-IL-17 TREATMENT
    Christoforou, T.
    Almanzar, G.
    Brauneiser, F.
    Buschmann, N.
    Feuchtenberger, M.
    Schmalzing, M.
    Tony, H. P.
    Goebeler, M.
    Prelog, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1318 - 1319
  • [34] Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA
    Iannone, F.
    Lopriore, S.
    Bucci, R.
    Scioscia, C.
    Anelli, M. G.
    Notarnicola, A.
    Lapadula, G.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2015, 44 (03) : 192 - 199
  • [35] Anti-IL-17 therapy rapidly decreases osteoclast activity in psoriatic patients: a novel quality in addition to its efficacy and safety
    Raimondo, Annunziata
    Lembo, Serena
    Caiazzo, Giuseppina
    Di Caprio, Roberta
    Balato, Anna
    ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY, 2021, 156 (02) : 231 - 234
  • [36] Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: A randomized, dose-escalation, placebo-controlled study
    Osamu, Nemoto
    Hirotaka, Nagashima
    Koji, Sayama
    Kenji, Takazawa
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2014, 75 (03) : 201 - 204
  • [37] EXPOSURE-RESPONSE MODELING OF LY2439821 (AN ANTI-IL-17 MONOCLONAL ANTIBODY) IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS.
    Tang, C.
    Choi, S.
    Satterwhite, J.
    Cameron, G.
    Banerjee, S.
    Tham, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S40 - S41
  • [38] Safety profile of ixekizumab, an anti-IL-17 monoclonal antibody, in chronic plaque psoriasis patients after at least 1 year of open label treatment
    Gordon, Kenneth
    Leonardi, Craig
    Braun, Daniel
    Cameron, Gregory
    Erickson, Janelle
    Lebwohl, Mark
    Heffernan, Michael
    Banerjee, Subhashis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB184 - AB184
  • [39] ANTI CITRULLINATED PEPTIDE ANTIBODY (ACPA) IN PATIENTS WITH PSORIATIC ARTHRITIS (PSA): CLINICAL RELEVANCE
    Huynh, D.
    Etzel, C.
    Cox, V.
    Kremer, J.
    Greenberg, J.
    Kavanaugh, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 673 - 673
  • [40] Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: Findings of the infliximab multinational psoriatic arthritis controlled trial (IMPACT)
    Antoni, Christian E.
    Kavanaugh, Arthur
    van der Heijde, Desiree
    Beutler, Anna
    Keenan, Gregory
    Zhou, Bie
    Kirkham, Bruce
    Tutuncu, Zuhre
    Burmester, Gerd R.
    Schneider, Udo
    Furst, Daniel E.
    Molitor, Jerry
    Keystone, Edward
    Gladman, Dafna D.
    Manger, Bernhard
    Wassenberg, Siegfried
    Weier, Ralf
    Wallace, Daniel J.
    Weisman, Michael H.
    Kalden, Joachim R.
    Smolen, Josef S.
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (05) : 869 - 876
12345